Special Issue "25th Anniversary of the Amyloid Hypothesis and Alzheimer Disease"
Deadline for manuscript submissions: 30 March 2018
Dr. Stephan Schilling
Alzheimer’s Disease (AD) represents the most prevalent neurodegenerative disorder and a serious threat to an aging society. Due to the increasing life expectancy in developing countries, patient numbers will increase multiple-fold within the decades to come. Based on this, AD now represents one of the greatest unmet medical needs. Most of the drugs that are currently in clinical development rely on the amyloid hypothesis, which was first mentioned 25 years ago. Among many others, inhibitors of the beta-secretase BACE, and monoclonal antibodies targeting Aβ, presumably represent the most advanced treatment approaches. However, alternative strategies, which address modified amyloid peptides or their toxicity, are currently being tested. The development of these compounds was accompanied, and significantly advanced, by imaging methods and tracer molecules. This Special Issue aims to provide a platform for reviewing of treatment approaches that are currently being developed, but also welcomes contributions on new molecules for the diagnosis and treatment of AD.
Dr. Birgit Hutter-Paier
Dr. Stephan Schilling
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Amyloid hypothesis
- Alzheimer’s disease
- Amyloid pathology
- Amyloid toxicity
- Anti amyloidogenic treatment strategies
- Amyloid imaging